Pharmacologic treatment of atrophic age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 21, Issue 3, 2010, Pages 190-196

  Mata, Nathan L ^a   Vogel, Roger ^a  

^a Sirion Therapeutics Inc   (United States)

Author keywords

Age related macular degeneration; Drusen; Dry AMD; Geographic atrophy; Lipofuscin; Retina; Retinal pigment epithelium; RPE

Indexed keywords

ACU 4429; ACU 449; AL 8309; AL 8309 A; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARC 1905; ASCORBIC ACID; AUTOANTIBODY; BETA CAROTENE; BIOLOGICAL MARKER; CILIARY NEUROTROPHIC FACTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5 INHIBITOR; COPPER; ECULIZUMAB; FENRETINIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; ISOTRETINOIN; MC 101; NT 501; OT 551; PERCEIVA; PROSTAGLANDIN E1; PROTEIN POT4; RAPAMYCIN; RETINAL; SEROTONIN AGONIST; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ZINC;

BINDING AFFINITY; CLINICAL TRIAL; COLOR VISION DEFECT; COMPLEMENT SYSTEM; CONTROLLED DRUG RELEASE; DARK ADAPTATION; DEGENERATIVE DISEASE; DIABETIC MACULAR EDEMA; DNA POLYMORPHISM; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; LIGHT DAMAGE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VISUAL IMPAIRMENT;

GEOGRAPHIC ATROPHY; HUMANS; MACULAR DEGENERATION;

EID: 77951297847     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833866c8     Document Type: Review

References (84)

1. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122:598-614.
2. Klein BE, Klein R. Forecasting age-related macular degeneration through 2050. J Am Med Assoc 2009; 301:2152-2153.
3. Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 2009; 223:401-410.
4. Martidis A, Tennant M. Age-related macular degeneration. 2nd edn. St. Louis: Mosby; 2004:; pp. 925-933.
5. Anderson DH,Mullins RF,Hageman GS, et al.Arole for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134:411-431.
6. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 2006; 103:2328-2333.
7. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20:705-732.
8. AREDS. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119:1417-1436.
9. Parodi MB, Virgili G, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev 2009; CD006537.
10. Dugel P. Sirolimus in the treatment of retinal diseases. Retina Today2009; 2-5.
11. Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001; 23:559-586.
12. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res 2004; 10:6382S-6387S.
13. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357:553-561.
14. Wegscheider BJ, Weger M, Renner W, et al. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative agerelated macular degeneration. Ophthalmology 2007; 114:738-742.
15. Vine AK, Stader J, Branham K, et al. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 2005; 112:2076-2080.
16. Sepp T, Khan JC, Thurlby DA, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci 2006; 47:536-540.
17. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48:257-293.
18. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114:2168-2173.
19. Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. J Am Med Assoc 2006; 296:301-309.
20. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in agerelated macular degeneration. Science 2005; 308:385-389.
21. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308:419-421.
22. Scholl HP, Fleckenstein M, Fritsche LG, et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One 2009; 4:e7418.
23. Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008; 632:273-292.
24. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355:1233-1243.
25. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699-3709.
26. Bok D, Yasumura D, Matthes MT, et al. Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 2002; 74:719-735.
27. Cayouette M, Behn D, Sendtner M, et al. Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse. J Neurosci 1998; 18:9282-9293.
28. Cayouette M, Gravel C. Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Hum Gene Ther 1997; 8:423-430.
29. LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci 1998; 39:592-602.
30. Liang FQ, Aleman TS, Dejneka NS, et al. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. Mol Ther 2001; 4:461-472.
31. Liang FQ, Dejneka NS, Cohen DR, et al. AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol Ther 2001; 3:241-248.
32. Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002; 43:3292-3298.
33. Aebischer P, Kato AC. Treatment of amyotrophic lateral sclerosis using a gene therapy approach. Eur Neurol 1995; 35:65-68.
34. Sagot Y, Tan SA, Baetge E, et al. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse. Eur J Neurosci 1995; 7:1313-1322.
35. Bazan JF. Neuropoietic cytokines in the hematopoietic fold. Neuron 1991; 7:197-208.
36. Helfand SL, Smith GA, Wessells NK. Survival and development in culture of dissociated parasympathetic neurons from ciliary ganglia. Dev Biol 1976; 50:541-547.
37. Varon S, Manthorpe M, Adler R. Cholinergic neuronotrophic factors: I. Survival, neurite outgrowth and choline acetyltransferase activity in monolayer cultures from chick embryo ciliary ganglia. Brain Res 1979; 173:29-45.
38. Stahl N, Yancopoulos GD. The tripartite CNTF receptor complex: activation and signaling involves components shared with other cytokines. J Neurobiol 1994; 25:1454-1466.
39. Peterson WM, Wang Q, Tzekova R, et al. Ciliary neurotrophic factor and stress stimuli activate the Jak-STAT pathway in retinal neurons and glia. J Neurosci 2000; 20:4081-4090.
40. Wahlin KJ, Campochiaro PA, Zack DJ, et al. Neurotrophic factors cause activation of intracellular signaling pathways in Muller cells and other cells of the inner retina, but not photoreceptors. Invest Ophthalmol Vis Sci 2000; 41:927-936.
41. Beltran WA, Zhang Q, Kijas JW, et al. Cloning, mapping, and retinal expression of the canine ciliary neurotrophic factor receptor alpha (CNTFRalpha). Invest Ophthalmol Vis Sci 2003; 44:3642-3649.
42. Fuhrmann S, Kirsch M, Heller S, et al. Differential regulation of ciliary neurotrophic factor receptor-alpha expression in all major neuronal cell classes during development of the chick retina. J Comp Neurol 1998; 400:244-254.
43. Seydewitz V, Rothermel A, Fuhrmann S, et al. Expression of CNTF receptoralpha in chick violet-sensitive cones with unique morphologic properties. Invest Ophthalmol Vis Sci 2004; 45:655-661.
44. Valter K, Bisti S, Stone J. Location of CNTFRalpha on outer segments: evidence of the site of action of CNTF in rat retina. Brain Res 2003; 985:169-175.
45. MacDonald IM, Sauve Y, Sieving PA. Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants. Can J Ophthalmol 2007; 42:399-402.
46. Williams GA, Tao W. A phase II study of encapsulated CNTF secreting cell implant (NT-501) in patients with visual acuity impairment associated with atrophic macular degeneration. 2009. ARVO. Ft. Lauderdale, Fl. Program # 5003.
47. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004; 10 (Suppl):S18-S25.
48. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11:298-300.
49. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45:115-134.
50. Hahn P, Milam AH, Dunaief JL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane. Arch Ophthalmol 2003; 121:1099-1105.
51. Ni J, Yuan X, Gu J, et al. Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics 2009; 8:1921-1933.
52. Gu X, Sun M, Gugiu B, et al. Oxidatively truncated docosahexaenoate phospholipids: total synthesis, generation, and peptide adduction chemistry. J Org Chem 2003; 68:3749-3761.
53. Sayre LM, Sha W, Xu G, et al. Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal. Chem Res Toxicol 1996; 9:1194-1201.
54. Ebrahem Q, Renganathan K, Sears J, et al. Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: implications for agerelated macular degeneration. Proc Natl Acad Sci U S A 2006; 103: 13480-13484.
55. Miyagi M, Sakaguchi H, Darrow RM, et al. Evidence that light modulates protein nitration in rat retina. Mol Cell Proteomics 2002; 1:293-303.
56. Tanito M, Li F, Elliott MH, et al. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci 2007; 48:1900-1905.
57. Reynolds A, Laurie C, Mosley RL, et al. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 2007; 82:297-325.
58. Zigler JS Jr, Qin C, Kamiya T, et al. Tempol-H inhibits opacification of lenses in organ culture. Free Radic Biol Med 2003; 35:1194-1202.
59. Renganathan K, Gu J, Collier R, et al. Drugs that prevent retinal light damage impact CEP biomarker levels. 2009. ARVO. Ft. Lauderdale, Fl. Program # 681.
60. Katz ML, Robison WG Jr. What is lipofuscin? Defining characteristics and differentiation from other autofluorescent lysosomal storage bodies. Arch Gerontol Geriatr 2002; 34:169-184.
61. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, et al. Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 2006; 47:2648-2654.
62. Schmitz-Valckenberg S, Bultmann S, Dreyhaupt J, et al. Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004; 45:4470-4476.
63. Schmitz-Valckenberg S, Fleckenstein M, Helb HM, et al. In vivo imaging of foveal sparing in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2009; 50:3915-3921.
64. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in agerelated macular degeneration. Am J Ophthalmol 2007; 143:463-472.
65. Schmitz-Valckenberg S, Fleckenstein M, Scholl HP, et al. Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol 2009; 54:96-117.
66. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005; 80:595-606.
67. Sparrow JR, Cai B, Jang YP, et al. A2E, a fluorophore of RPE lipofuscin, can destabilize membrane. Adv Exp Med Biol 2006; 572:63-68.
68. Zhou J, Jang YP, Kim SR, et al. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci U S A 2006; 103:16182-16187.
69. Iriyama A, Inoue Y, Takahashi H, et al. A2E, a component of lipofuscin, is proangiogenic in vivo. J Cell Physiol 2009; 220:469-475.
70. Mata NL, Weng J, Travis GH. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci U S A 2000; 97:7154-7159.
71. Weng J, Mata NL, Azarian SM, et al. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 1999; 98:13-23.
72. Radu RA, Mata NL, Nusinowitz S, et al. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci U S A 2003; 100:4742-4747. (Pubitemid 36457800)
73. Radu RA, Mata NL, Nusinowitz S, et al. Isotretinoin treatment inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Novartis Found Symp 2004; 255:51-63. (Pubitemid 44844405)
74. Kubota R, Birch D, David R. Phase 1, dose-escalating study of the safety, tolerability, and pharmacokinetics of ACU-4429 in healthy volunteers. 2009. ARVO. Ft. Lauderdale, Fl. Program # 5009.
75. Locke K, Caniano G, Tzekov R, et al. Electroretinographic (ERG) and psychophysical testing of normal subjects given a single dose of a visual cycle modulator (all-trans-N-retinylacetamide). 2009. ARVO. Ft. Lauderdale, Fl. Program # 967.
76. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005; 46:4393-4401.
77. Bui TV, Han Y, Reid S, et al. Reduction of serum retinol binding protein arrests the accumulation of toxic retinal fluorophores: a nonpharmacological approach. 2007. ARVO. Ft. Lauderdale, Fl. Program # 3244.
78. Katz RS, Vogel R, McLeod K. A phase II multicenter, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration: preliminary demographic data and reasons for screen failure 2009. ARVO. Ft. Lauderdale, Fl. Program # 4918.
79. Vogel R, Slakter J, McLeod K. A phase II, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration: baseline lesion size, characteristics, and preliminary progression data 2009. ARVO. Ft. Lauderdale, Fl. Program # 4919.
80. Friedman E, Krupsky S, Lane A, et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology 1995; 102:640-646.
81. Grunwald J, Hariprasad S, DuPont J, et al. Foveal choroidal blood flow in agerelated macular degeneration (AMD). Invest Ophthalmol Vis Sci 1998; 39:385-390.
82. Grunwald J, Metelitsina T, DuPont J, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46:1033-1038.
83. Sunness JS, Margalit E, Srikumaran D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration. Ophthalmology 2007; 114:271-277.
84. Fleckenstein M, Adrion C, Schmitz-Valckenberg S, et al. Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci 2010; 50:3915-3921.